Visit EmeritusDX at ACG (Booth 1635) & AAPM&R (Booth 2635) | Explore Our Solutions
Client Services:800-959-2846|Billing:949-374-5019
Hematopathology offerings
Flow Cytometry
Flow Cytometry
Flow Cytometry
Our advanced 13-color, 15-parameter flow cytometry evaluates multiple markers simultaneously within a single tube, providing greater diagnostic insight while reducing the number of tubes required. This approach supports comprehensive characterization of abnormal cell populations to help diagnose, classify, and monitor hematologic malignancies. Most cases are reported the same day they are received, to support timely clinical decision-making.
Morphology
Flow Cytometry
Flow Cytometry
Comprehensive morphologic evaluation is supported by a broad antibody panel tailored specifically for hematopathology. Immunohistochemistry (IHC) and special stains enhance lineage determination and provide essential tools for accurate subclassification of neoplastic diseases. Together, these diagnostic approaches ensure clarity and confidence in complex case evaluation.
FISH
Flow Cytometry
Molecular
FISH is a highly sensitive technique used to detect specific genetic abnormalities at the chromosomal level. By using fluorescent probes to identify gene rearrangements, amplifications, and deletions, FISH provides critical diagnostic and prognostic information for hematologic malignancies and solid tumors. These insights help guide accurate diagnosis, risk stratification, and targeted treatment decisions.
Molecular
Next-Generation Sequencing
Molecular
Our molecular diagnostics testing identifies clinically significant genetic mutations associated with cancer and other diseases. Using advanced PCR-based and targeted molecular techniques, we detect actionable biomarkers that support diagnosis, prognosis, and personalized therapy selection. This precise genetic information enables clinicians to make more informed treatment decisions and improve patient outcomes.
Cytogenetics
Next-Generation Sequencing
Next-Generation Sequencing
Cytogenetic analysis evaluates the structure and number of chromosomes to identify abnormalities associated with malignancies and genetic disorders. Through conventional karyotyping and specialized techniques, our cytogenetics team detects chromosomal gains, losses, and rearrangements that are essential for diagnosis, classification, and prognostic assessment—particularly in leukemia, lymphoma, and bone marrow disorders.
Next-Generation Sequencing
Next-Generation Sequencing
Next-Generation Sequencing
Next-Generation Sequencing (NGS) provides comprehensive analysis of multiple genes simultaneously to identify clinically relevant mutations. This powerful technology enables detection of actionable genomic alterations that support precise diagnosis, prognostic evaluation, and targeted therapy selection. NGS plays a critical role in advancing personalized medicine and improving cancer care.
synatra™
SYNATRA™ Personalized Resulting System
- Proprietary case assessment platform developed at EmeritusDX
- Integrates all medically necessary technologies into one patient-specific report
- Supports precise, personalized clinical decision-making
Our hematopathology services provide:
- Accurate Classification of hematologic neoplasms
- Actionable Prognostic Information to support personalized treatment
- Predictive Insights for therapy selection and patient monitoring
- Rapid Turnaround Times to meet urgent clinical needs
13-color, 15-parameter flow cytometry
Greater Insight into Abnormal Cell Populations
EmeritusDX’s advanced flow cytometry evaluates multiple markers simultaneously within a single tube, providing a more complete picture of abnormal cell populations while reducing the number of tubes required. This approach supports the diagnosis, classification, and monitoring of hematologic malignancies
BCR-ABL
Quantitative molecular testing for BCR-ABL
Highly sensitive quantitative PCR testing for accurate detection and
monitoring of BCR-ABL1 transcript levels, supporting treatment
decisions and long-term disease management in CML patients.
BCR-ABL1 FISH
Detection of BCR-ABL1 gene rearrangements
BCR-ABL1 FISH uses fluorescence in situ hybridization (FISH) to detect BCR-ABL1 gene rearrangements in patient specimens. Testing provides valuable cytogenetic information to support the diagnosis and classification of hematologic malignancies associated with BCR-ABL1.
jak2
Comprehensive molecular testing for the detection of JAK2 mutations
Accurate molecular testing for JAK2 mutations associated with myeloproliferative neoplasms (MPNs), providing valuable diagnostic information to support disease classification, treatment decisions, and ongoing patient management.
MDS FISH
Targeted FISH testing for MDS-associated abnormalities
MDS FISH testing helps identify clinically significant chromosomal abnormalities associated with myelodysplastic syndromes, providing valuable information to support diagnosis, disease classification, prognosis, and patient management.
CLL FISH
CLL FISH uses fluorescence in situ hybridization to detect
recurrent chromosomal abnormalities associated with Chronic
Lymphocytic Leukemia (CLL). The panel evaluates clinically
relevant genetic changes that can provide important
information for disease characterization, prognosis, and
patient management.